Kansas is currently home to 890 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Central Care Cancer Center - Garden City, Garden City, Kansas
Conditions: Plasma Cell Myeloma
Register for Updates
Implementation & Dissemination of a Digital Health Intervention for Adolescent Sleep
NCT06840444
Recruiting
The goal of this study is to form a Teen Advisory Board (TAB), who will partner with our study team to co-design a beta-test a new prototype of the Firefly program, a mobile-native insomnia cognitive behavioral therapy intervention for teens. This new prototype will have addressed issues that adolescents who had used the first version of the program deemed to be barriers to engaging with the treatment.
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
05/28/2025
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Insomnia, Adolescent, Digital Health
Register for Updates
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)
NCT06636786
Recruiting
This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled randomized clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats/... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/28/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Clinical Study Site, Westwood, Kansas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333
Recruiting
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Kansas Medical Center (KUMC), Kansas City, Kansas
Conditions: Congestive Heart Failure
Register for Updates
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
NCT04835428
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Register for Updates
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648
Recruiting
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a... Read More
Gender:
FEMALE
Ages:
Between 22 years and 77 years
Trial Updated:
05/23/2025
Locations: Cypress Medical Research Center, Wichita, Kansas
Conditions: Stress Urinary Incontinence (SUI)
Register for Updates
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
NCT06279013
Recruiting
In this clinical trial, symptom monitoring (interactive voice response \[IVR\] is compared to automated telephone symptom management \[ATSM\] and telephone interpersonal counseling \[TIPC\]) for reducing symptom burden and psychological distress (depressive and anxiety symptoms) among people receiving oral anti-cancer treatment. Symptoms are the number one driver of treatment interruptions and unscheduled health services use. To reduce the risk of these events, symptom monitoring and management... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Central Care Cancer Center - Garden City, Garden City, Kansas
Conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT06154447
Recruiting
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Altasciences Clinical Kansas, Overland Park, Kansas
Conditions: Cystic Fibrosis
Register for Updates
Clinical Procedures to Support Research in ALS
NCT03489278
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Register for Updates
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT06034002
Recruiting
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: The University of Kansas Cancer Center, Westwood, Kansas
Conditions: Myeloproliferative Neoplasms
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Cancer Center of Kansas, Wichita, Kansas
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates